The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'


Mylan bags FDA?s tentative approval for fixed-dose HIV combo therapy.....           Orano Med, RadioMedix recruit first patients in AlphaMedix phase 1 clinical trial.....           Tetraphase, Everest sign licensing deal for cIAI drug eravacycline in China.....           BerGenBio completes recruitment into first stage of phase II breast cancer trial.....           Sterna reports positive results in severe ulcerative colitis drug trial.....           AstraZeneca's Imfinzi breaks new I-O ground with landmark $1B lung cancer nod.....           Merck CEO speaks up on Trump: Charlottesville response defied our country's 'basic values'.....           Former Teva generics chief Olafsson steps into CEO seat at growth-challenged Hikma.....           Gilead wins reversal of $2.54B hepatitis C patent verdict, but Merck says fight not over yet.....           Flucelvax, Fluad propel Seqirus to 26% sales growth in H1.....           Lilly?s Taltz yields positive results in phase 3 genital psoriasis trial.....           DanDrit Biotech acquires gene therapy company Enochian Biopharma.....           Could Apple?s move into EHR allow pharma to connect directly to patients?.....           Seikagaku begins phase 3 US trial for SI-6603 for lumbar disc herniation.....           Novartis' Cosentyx improves skin clearance in scalp psoriasis study.....           AstraZeneca's Imfinzi wins FDA approval for lung cancer treatment.....           Teva launches QVAR RediHaler inhalation aerosol in US.....           Mixed feelings? Havas tackles the emotional motivations behind healthcare decisions with new agency.....           FiercePharmaAsia?Astellas acquisition, Teva?s Celltrion problem, Korea?s digital health initiative.....           Remicade biosims from Pfizer, Merck unlikely to turn the tide in 2018: analyst.....           AbbVie, Allergan, Roche could join Biogen, UCB in Acorda hunt: analyst.....           FDA Form 483 shows Pfizer repeating same mistakes at troubled fill-finish plant.....           Pfizer's Bavencio flops third key study, this time in lung cancer. Can crossover really explain it?.....           Roche to buy oncology software provider Flatiron Health for $1.9bn.....           GSK?s Fluarix Tetra wins European approval for expanded indication.....           FDA grants orphan drug designation to Selumetinib for neurofibromatosis type 1.....           Cancer Research UK announces £45m investment in clinical trials.....           Pharma unleashes lobbying power to fight surprising?and costly?changes to Medicare Part D.....           Johnson & Johnson?s stay-out-of-jail marketing for schizophrenia blockbuster Invega Sustenna raises eyebrows.....           Teva gets a boost as billionaire Buffett reports $358M stake.....           Horizon's faced repeated price-hike criticism, but Vimovo just got its 11th raise?to almost $3,000.....           Vertex cancels plans for CF triple combo testing in France, citing failed Orkambi negotiations.....           Janssen?s Erleada wins FDA nod for nonmetastatic prostate cancer.....           Astellas Pharma acquires Universal Cells for $102m.....           Veloxis secures $60m capital from Athyrium Capital.....           Bayer says warning letter resulted in some product supply issues.....           FDA gives Johnson & Johnson's Erleada a quick push over the finish line with first-ever nonmetastatic prostate cancer nod.....           Beat you to it, Purdue. Other opioid makers already ditched promotions.....           Lilly chases third Taltz-Cosentyx matchup with new ankylosing spondylitis data.....           Merck says Keytruda's explosive growth prompts need for new Ireland plant with 350 jobs.....           Axovant COO McCourt jumped from sinking biotech right into Regeneron's top commercial post.....           Ex-Merck chemist faces prison for allegedly dumping cyanide.....           Bayer says warning letter resulting in some product supply issues.....           For Shire, more margin pressure plus fewer growth sparks make for underwhelming 2018.....           FDA gives J&J's Erleada a quick push over the finish line with first-ever nonmetastatic prostate cancer nod.....           Novartis secures FDA approval for larger dosage of MS drug Glatopa.....           Bill Gates foundation awards grants to mRNA vaccine developer CureVac.....           Lilly?s radiographic axial spondyloarthritis treatment Taltz succeeds in phase 3 study.....           Who won and who lost in tax reform? AbbVie, of course, but Regeneron, Roche, AstraZeneca and more.....           UK?s NICE recommends Eusa Pharma?s Fotivda to treat advanced renal cell carcinoma.....           Novartis pushes past manufacturing slowdown to launch second long-acting Copaxone copy.....           Drugmakers paid $10M+ to groups that pushed wide opioid use, investigation finds.....           Celgene ex-CEO Hugin launches Senate run in New Jersey amid protest from drug-price critics.....           FDA nod for Vertex's improved CF combo, Symdeko, opens $200M door this year.....           GlaxoSmithKline tops its peers with $7.16B in 2017 vaccine sales.....           Vertex?s Symdeko cystic fibrosis drug secures FDA approval.....           Horizon Discovery out-licenses cell line engineering technology to US firm.....           Diurnal Group completes patient enrolment in Chronocort?s trial for congenital adrenal hyperplasia.....           Pharma and AI: Help doctors with AI assistants but don?t try to replace them.....           Purdue Pharma finally stops marketing opioids to physicians?and cuts 200-plus representatives in the process.....           Regeneron's Eylea still sitting pretty even after new data from would-be rivals Roche, Novartis: analyst.....           Pharma will pay more under the new budget deal?and some long-suffering pharmas will pay the most.....           As raging flu epidemic spreads, Sanofi Pasteur targets more effective cell-based universal vaccine.....           No new patients for Allergan's fibroid drug Esmya, EMA advises amid liver-damage probe.....           Apalutamide delays spread of several prostate cancers in phase 3 trial.....           Novo Nordisk?s Ozempic secures European approval for type 2 diabetes.....           Seattle Genetics, Pieris enter into $1.2bn immuno-oncology collaboration.....           Roivant, Poxel to develop and commercialise imeglimin in US, Europe and additional countries.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
 
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
 
 
APS events overview

The APS has developed an exciting and informative programme for our events in 2018.

We are re-running the Developability Workshop and Regulatory Essentials training events which have proved enormously popular when run before.

In March, we have the first one of our collaborative meetings, 'Emerging technologies in therapeutic oligonucleotides', hosted by MedImmune, followed by 'APS Current Regulatory trends and updates in parenteral drug product development' that will be informative and interactive describing the current regulatory requirements, especially focusing on recent changes in guidelines, as well as covering topical issues, trends and developments in the wider field of parenteral products.

Don’t forget to make a note of APS@FIP, linking with the 78th FIP World Congress of Pharmacy and Pharmaceutical Science conference.

Please take a look at our programme, with event summaries, below:

Emerging technologies in therapeutic oligonucleotides
13 March 2018 - MedImmune, Cambridge
MedImmune, AstraZeneca and GE Healthcare Life Sciences, in partnership with GSK, Roche, University of Oxford, BioMax and Academy of Pharmaceutical Sciences are pleased to invite you to their sixth oligonucleotide networking event.
To learn more and to register, click here

APS Current Regulatory trends and updates in parenteral drug product development
20 - 21 March 2018 - Burleigh Court, Loughborough University
This residential course is aimed at pharmaceutical scientists and regulatory affairs professionals involved in the development, manufacture, control or registration of parenteral products. Speakers will include key industry and MHRA experts.
To learn more and to register, click here

APS Industrial Insights
26 - 27 March 2018 - Pfizer / Mylan at Discovery Park, Sandwich
An event for undergraduate and postgraduate students interested in exploring opportunities in the Pharmaceutical Industry, through a series of talks by pharmaceutical scientists working within the industry as well as a tour of the Pfizer Research and Development facilities.
To learn more and to register, click here

Accelerating paediatric formulation development
Presentation of output from SPaeDD-UK Project

28 March 2018 - Friends House, London
The Smart Paediatric Drug Development (SPaeDD) initiative co-funded by Innovate UK (the UK’s Innovation Agency) is a cross company and academic centre initiative to accelerate paediatric formulation development. The collaboration has now reached the end of its funding period and this meeting will present the final outputs from the project work streams. Each of these has produced outputs which will no doubt significantly assist the way in which medicines are developed and tested for children.
To learn more and to register, click here

APS Developability Workshop
10 - 11 April 2018 - Granta Park, Cambridge
Learn from a pharmaceutics and biopharmaceutics perspective what is required to assess a molecule in discovery and its suitability for ‘candidate selection’; determine how ‘developable’ it is with associated risk, time and cost implications; and what is needed to progress it through pre-clinical studies and into Phase 1 and 2a clinical studies to achieve Proof of Concept.
To learn more and to register, click here

APS Regulatory Essentials II
22—23 May 2018 - Burleigh Court, Loughborough University
This is a residential course aimed at pharmaceutical scientists and regulatory/quality professionals in originator and generics’ companies who will benefit from gaining a better appreciation of key elements in the development and registration of oral dosage forms.
To learn more and to register, click here

APS@FIP
7 September 2018 - Hilton Hotel, Glasgow
Linking with the 78th FIP World Congress of Pharmacy and Pharmaceutical Science conference, which will take place in the city from the 2 - 6 September 2018. The theme of this conference in 2018 is 'The Science of Differentiated Medicines'.
To learn more and to register, click here

OTHER EVENTS IN DEVELOPMENT
Developability for Biologicals
Inhaled Workshop
Basic Biopharmaceutics workshop
Nanomedicine drug delivery: Opportunities and Challenges
OrBiTo (Innovative Tools for Oral Biopharmaceutics) Conference

 
 

Reflections on APS PharmSci 2017 Conference

Date: 5 - 7 September 2017
Location: De Havilland Campus, University of Hertfordshire, Hatfield
Conference Chair: Professor Abdul Basit (University College London)
Theme: Pharmaceutical Science without Borders


A very successful 3-day conference provided an excellent interactive face to face forum for exchange of knowledge and sharing learnings and experiences in many aspects of the pharmaceutical sciences. With 80+ inspiring speakers and over 390 delegates joined together from academia, the Pharmaceutical Industry, and service companies. During the sessions, there was a steady flow of discussion which continued into the breaks and around the exhibition stands and posters.
 

Young pharmaceutical scientists had their first opportunity to present either a poster or podium presentation (or indeed both!) which is a major strength of APS PharmSci.

 

Read more, as Linda Hakes (Retiring APS Chair) and Mark McAllister (APS Chair) talk about their experiences at this year’s PharmSci.

Latest News
RPS Excellence in Pharmaceutical Science Excellence in Pharmaceutical Science Award
WEDNESDAY, 10 MAY 2017
Excellence in Pharmaceutical Science recognises those who have delivered proactive and innovative projects and initiatives that lead the way in pharmaceutical science. . The nominee should have demonstrated excellence in pharmaceutical science, by showing innovation and initiative, and contributing to a project which has had an impact on the improvement of pharmaceutical science.. To download the nomination form, please visit us online here:. https://www.rpharms.com/events/rps-awards. To be considered for the nomination the nominee must cover all aspects in the criteria. Completed nomination forms should be sent to events@rpharms.com by Monday 29 May 5pm..
Applications invited for the 2017 Royal Pharmaceutical Society Science Award
TUESDAY, 9 MAY 2017
Applications are invited for the 2017 Royal Pharmaceutical Society Science Award. The winner will receive a Commemorative Award, £1,000 in prize money and an invitation to present the RPS Award Lecture on their work at the Academy of Pharmaceutical Sciences International PharmSci Conference meeting on Thursday 7th September 2017.. Applications are welcome from scientists world-wide who are working in a pharmaceutical or allied discipline in industry or academia. With up to 10 years experience at post-doctoral level in September 2017, applicants must have a proven record of independent research and published work that shows outstanding promise. . Applicants are invited to submit the following details by 31st May 2017: . · Full CV detailing personal information, past and present appointments, research responsibilities and published work. . · List of research students who have worked for the applicant and their thesis titles and dates, plus any other instances of research collaborations . · Details of research grants awarded and the candidate’s role . · Invitations to speak at conferences in the UK and overseas, lecture or symposium titles and names of awards . · A brief resume of two pages should also be submitted with the CV, indicating discoveries made (please note copies of publications are not required). . Submissions should be sent to: evidence@rpharms.com or by post to: Rachel Joynes, Head of Research Royal Pharmaceutical Society 66-68 East Smithfield London E1W 1AW. .
APS 8th International PharmSci Conference 2017 Call for Abstracts
THURSDAY, 12 JANUARY 2017
. 'Pharmaceutical Sciences Without Borders’. Tuesday 5 – Thursday 7 September 2017 De Havilland Campus of the University of Hertfordshire in Hatfield. Call for Abstracts. Abstracts are invited for posters for APS International PharmSci 2017. This is one of the most exciting parts of the conference as it represents the presentation of the very latest pharmaceutical science research.. Abstracts on any aspect of the Pharmaceutical Sciences are welcomed and those with a particular emphasis on the theme of this year’s Conference, 'Pharmaceutical Sciences Without Borders’ are particularly appreciated. Details of the various subject categories, an abstract template and details of the entry process can be found here:. http://www.ukpharmsci.org/abstracts/default.asp. Please ensure abstracts are submitted online and comply with the Abstract Submission Template. Please note one or two page abstracts are welcomed providing they follow the template.. There will be prizes awarded for winning posters on each day of the Conference and authors of abstracts of particular interest will be invited to give podium presentations (15min). This is an excellent chance to get your science recognised at the UK’s premier Pharmaceutical Science Conference. The closing date for abstract submission is Friday 17th March 2017.. Abstracts will be made available to Conference registrants when the abstract author has registered for the Conference. We also intend to publish the abstracts in a journal after the Conference and authors not wishing to take up this opportunity are requested to indicate this where indicated when they submit their abstract.. Entrants in the Analytical Chemistry category may be eligible for the Geoffrey Phillips Analytical Science Award, subject to meeting the criteria, awarded by the Joint Pharmaceutical Analysis Group (JPAG). The purpose of the Award is to encourage the advancement of pharmaceutical analysis and to recognise contributions of emerging scientists reporting wholly or mainly their own work. The winner receives a prestigious award with a bursary of up to £1000 to attend a conference relevant to their area of interest.. http://www.jpag.org/?&sid=20170112135948802597&p=awards#award. Exhibitor Opportunities. The conference includes a large pharmaceutical sciences exhibition, which is open to large pharma companies, small and medium size enterprises (SMEs), contract research organisations (CROs) and technology suppliers. With one of the largest gatherings of pharmaceutical scientists in the UK, the conference offers a great opportunity to showcase your company.. For more information please contact us: info@apsgb.org or 0116 274 7351. .
APS Fellowships Announcement 2017
WEDNESDAY, 2 NOVEMBER 2016
Do you know someone who has made a significant contribution to Pharmaceutical Science?. The APS is calling for nominations of candidates to become Fellow or Eminent Fellow of the Academy of Pharmaceutical Sciences.. Nominees for Fellowship must be a member of APS (for at least one year) and have a proven track record in pharmaceutical science, as demonstrated by at least 15 peer-reviewed publications, patents or equivalent. This would include significant contributions to the development of products or medical devises within the pharmaceutical industry. Nominees must also have demonstrated leadership and peer recognition through invited lectures, conference leadership, mentoring of young scientists etc. Candidates may self-nominate and nominations must consist of a one-page summary of achievements accompanies by a CV.. Nominations for Eminent Fellowship may be submitted by any member of APS but self-nominations are not accepted. Nominees for Eminent Fellowship must have international recognition for their advocacy of science and have demonstrated leadership at international level. Nominations should consist of a one-page summary of achievements and an explanation of why Eminent Fellowship is justified, and be accompanied by a CV.. Nominations should be sent to info@apsgb.org by 1 March 2017.

Follow us
 
Upcoming Events
Emerging technologies in therapeutic oligonucleotides
13 March 2018
APS Current Regulatory trends and updates in parenteral drug product development
20 - 21 March 2018
APS Industrial Insights
26 - 27 March 2018
Accelerating paediatric formulation development
Presentation of output from SPaeDD-UK Project

28 March 2018
APS Developability Workshop
10 - 11 April 2018
Job Vacancies
View all Vacancies
Advertise your job vacancies
The APS is grateful for the support of:
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.

 

The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365
Email: info@apsgb.org

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.